Figure 5

Effect of GPI-scFv (X5) on anti-HIV-1 activity of transduced human CD4⁺ T cells. A.GPI-scFv (X5) confers long-term resistance to HIV-1 Bru-3 in human CD4⁺ T cells. sec-AB65: CEMss-CCR5 cells transduced with secretory scFv (AB65); sec-X5: CEMss-CCR5 cells transduced with secretory scFv (X5); GPI-AB65: CEMss-CCR5 cells transduced with GPI-scFv (AB65); GPI-X5: CEMss-CCR5 cells transduced with GPI-scFv (X5). B.GPI-scFv (X5) confers long-term resistance to HIV-1 Bru-Yu2 in human CD4⁺ T cells. C.Western blot analysis of HIV-1 gp160, gp120 and gp41 expression by anti-HIV-1 gp120 and gp41 antibodies in 69 T1RevEnv cells with or without treatment of tetracycline. Lane 1: 69 T1RevEnv cells without treatment of tetracycline stained with anti-HIV-1 gp41 antibody; lane 2: 69TiRevEnv cells with treatment of tetracycline stained with anti-HIV-1 gp41 antibody; lane 3: 69TiRevEnv cells without treatment of tetracycline stained with anti-HIV-1 gp120 antibody; lane 4: 69TiRevEnv cells with treatment of tetracycline stained with anti-HIV-1 gp120 antibody. D.Cell morphology 20 hours after coculturing tetracycline-treated 69TiRevEnv cells with CEMss-CCR5-GPI-scFv (AB65). E.Cell morphology 20 hours after coculturing tetracycline-untreated 69TiRevEnv cells with CEMss-CCR5-GPI-scFv (AB65). F.Cell morphology 20 hours after coculturing tetracycline-treated 69TiRevEnv cells with CEMss-CCR5-GPI-scFv (X5). G.Cell morphology 20 hours after coculturing tetracycline-untreated 69TiRevEnv cells with CEMss-CCR5-GPI-scFv (X5). H.GPI-scFv (X5) blocks the infection of HIV-1captured and transferred by human DCs. GPI-X5: co-culturing infected human DC with CEMss cells transduced with GPI-scFv (X5); GPI-AB65: co-culturing infected human DC with CEMss cells-transduced with GPI-scFv (AB65).